ĐÁNH GIÁ HIỆU QUẢ ĐIỀU TRỊ SUY TIM PHÂN SUẤT TỐNG MÁU THẤT TRÁI GIẢM BẰNG PHỐI HỢP THUỐC DAPAGLIFLOZIN TẠI BỆNH VIỆN ĐA KHOA BẠC LIÊU NĂM 2023-2024

Abstract

Background: Heart failure is a complex clinical syndrome with a high mortality rate. Patients with heart failure with reduced ejection fraction (HFrEF) have a 5-year survival rate of only about 25%. Dapagliflozin has been shown in multiple studies to improve clinical symptoms and reduce cardiovascular mortality and heart failure hospitalizations in patients with heart failure with reduced ejection fraction. Objectives: To describe the clinical and paraclinical characteristics and evaluate the effectiveness of treatment in patients with heart failure with reduced left ventricular ejection fraction after treatment with the drug combination dapagliflozin. Material and method: 74 patients with heart failure with reduced left ventricular ejection fraction were treated with a basic regimen including dapagliflozin. The research method was a descriptive cross-sectional study with nonprobability random sampling and no control group. Results: Our study recorded that clinical symptoms dyspnea accounted for a high rate of 95.9%, with an average EF% of 37.1±5.8%. Pro BNP mean value 15938.1±42732.8. Patients with improvement accounted for a high proportion in our study, accounting for 89.2%, rehospitalization for heart failure accounted for 8.1%. %, cardiovascular mortality accounts for 2.7%. The average KCCQ score increased significantly after 4 weeks and 12 weeks compared to the time of admission and all changes were statistically significant (p<0.001). Conclusion: Our study noted that dyspnea is the most common clinical symptom in patients with heart failure with reduced left ventricular ejection fraction. Dapaglifozin reduces the rate of rehospitalization for heart failure and cardiovascular death. The average KCCQ score increased significantly after 4 weeks and 12 weeks of treatment compared to the time of admission.